Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

2026.02.03
On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.
From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

From Evidence-Based Medicine to Strategic Sequencing: Rethinking and Breaking Through Whole-Course Immunotherapy in Urothelial Carcinoma

2026.02.03
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The conference brought together the emerging backbone of China’s urologic oncology community, aiming to promote standardized and innovative development in the diagnosis and treatment of urologic malignancies through cutting-edge academic discussion and clinical experience sharing.
CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

CASH 2026 | Professor Hui Wei: Frontiers in Precision Therapy for AML and New Management Pathways for High-Risk Patients

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.
CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

CASH 2026 | Professor Lanping Xu: Advances and Optimization Strategies in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

2026.02.01
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.
Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)

Annual Review | Professor Wei Xu: New Trends and Future Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)

2026.02.01
From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions, offering valuable insights for optimizing clinical practice.
2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2026.01.31
The 2025 Yixian Breast Cancer Conference, held alongside the 2025 CSCO Breast Cancer Southern Forum, the Second Chinese Young Breast Cancer Consensus Conference, and the Fourth Yixian Breast Cancer Nursing Conference, took place in Guangzhou on December 26–27, 2025. The meeting focused on standardization of breast cancer care, emerging therapeutic strategies, and precision management in young breast cancer patients, highlighting the latest scientific advances and future clinical directions.
Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

2026.01.31
Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As modern breast surgery moves toward precision and minimally invasive approaches, sentinel lymph node biopsy (SLNB) has replaced ALND as the preferred axillary staging strategy, significantly reducing surgical trauma and complications.
Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

Lymphoma Frontline Advances | Professor Qingqing Cai: Breakthrough Progress in First-Line Bispecific Antibody Therapy for Lymphoma — ASH 2025 Special

2026.01.30
The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma Insights – ASH Special” series, delivering authoritative interpretation of landmark lymphoma studies with practical clinical relevance.
CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

CASH 2026 | Professor Zhigang Cai: Breakthrough Advances in Clonal Hematopoiesis, MDS, MPN, and VEXAS Syndrome

2026.01.30
From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.